LOCB
ALXN

Lombard Odier & Cie (Bahamas)’s Alexion Pharmaceuticals ALXN Stock Holding History

Lombard Odier & Cie (Bahamas)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,500
Closed -$580K – 93
2014
Q3 		$580K Hold
3,500
– – 0.21% 50
2014
Q2 		$547K Hold
3,500
– – 0.2% 48
2014
Q1 		$532K Hold
3,500
– – 0.21% 46
2013
Q4 		$466K Buy
+3,500
New +$420K 0.18% 55

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Lombard Odier & Cie (Bahamas)'s ALXN Position: Q4 2014 in Review

Lombard Odier & Cie (Bahamas) sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 3,500 shares — an estimated $580K sold.

Lombard Odier & Cie (Bahamas) first reported a position in ALXN in Q4 2013 and held it in 4 quarters. The position peaked at $580K in Q3 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Lombard Odier & Cie (Bahamas) reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Lombard Odier & Cie (Bahamas) sold 3,500 Alexion Pharmaceuticals shares in Q4 2014, an estimated $580K.
  • Lombard Odier & Cie (Bahamas) first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 4 quarters.
  • Lombard Odier & Cie (Bahamas)'s Alexion Pharmaceuticals position peaked at $580K in Q3 2014.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Lombard Odier & Cie (Bahamas)'s 13F filing for Q4 2014, filed 13 Feb 2015.